stockrowSepterna, Inc.
SEPN Healthcare Biotechnology
Septerna, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $46.0 million, up 4,174.5% from fiscal 2024.
- Revenue
- +22,375.6%
- EPS
- +48.2%
- Free cash flow
- −9.01%
Quarter to June 2026, against a year earlier
Follow SEPN
Alert me
Septerna, Inc. (SEPN) Return on invested capital
Septerna, Inc.'s return on invested capital over the twelve months to 30 June 2026 was −189.0%, down 189.0 percentage points from fiscal 2025 (0.00%). That is below the Biotechnology industry median of 0.00% and below the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | 0.00% | 73.08 |
| FY2024 | −73.1% | (73.08) |
| FY2023 | 0.00% | — |
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| AUPH Aurinia Pharmaceuticals Inc compare | 43.0% |
| VCEL Vericel Corporation compare | 7.88% |
| VERA Vera Therapeutics, Inc. compare | 0.00% |
| ZYME Zymeworks Inc. compare | 0.00% |
| LKFT Lakefront Biotherapeutics - Sponsored ADR compare | 0.00% |
| PVLA Palvella Therapeutics, Inc. compare | 0.00% |
| SEPN Septerna, Inc. | −189.0% |
| IMNM Immunome, Inc. compare | −3,323.0% |
| BHVN Biohaven Ltd. compare | −6,659.9% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)
More on SEPN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- The full statement